Cart
sales@molnova.com
Tepotinib hydrochloride(1 : x)
CAS No. 1103508-80-0
Tepotinib hydrochloride(1 : x)( —— )
Catalog No. M28794 CAS No. 1103508-80-0
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 302 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTepotinib hydrochloride(1 : x)
-
NoteResearch use only, not for human use.
-
Brief DescriptionTepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
-
DescriptionTepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.(In Vitro):Tepotinib hydrochloride(1 : x) potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, Tepotinib hydrochloride(1 : x) inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. Tepotinib hydrochloride(1 : x) synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorPAK1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1103508-80-0
-
Formula Weight529.04
-
Molecular FormulaC29H29ClN6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.McCoull W, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016 Sep 14;7(12):1118-1123. eCollection 2016 Dec 8.
molnova catalog
related products
-
JNJ-38877618
JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor.
-
MK-2461
MK-2461 is a potent multitargeted kinase inhibitor that preferentially inhibits c-Met with IC50 of 2.5 nM.
-
Tyrosine kinase inhi...
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
